Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Hdl Handle:
http://hdl.handle.net/10147/107733
Title:
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.
Authors:
Hampel, Harald; Shen, Yong; Walsh, Dominic M; Aisen, Paul; Shaw, Les M; Zetterberg, Henrik; Trojanowski, John Q; Blennow, Kaj
Affiliation:
Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience (TCIN), Laboratory of Neuroimaging and Biomarker Research, Trinity College Dublin, Trinity Centre for Health Sciences, The Adelaide and Meath Hospital Incorporating The National Children's Hospital (AMiNCH), Dublin, Ireland; Department of Psychiatry, Alzheimer Memorial Center, Ludwig Maximilian University, Munich, Germany.
Citation:
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. 2010, 223 (2):334-46 Exp. Neurol.
Journal:
Experimental neurology
Issue Date:
Jun-2010
URI:
http://hdl.handle.net/10147/107733
DOI:
10.1016/j.expneurol.2009.09.024
PubMed ID:
19815015
Abstract:
Recent research progress has given detailed knowledge on the molecular pathogenesis of Alzheimer's disease (AD), which has been translated into an intense, ongoing development of disease-modifying treatments. Most new drug candidates are targeted on inhibiting amyloid beta (Abeta) production and aggregation. In drug development, it is important to co-develop biomarkers for Abeta-related mechanisms to enable early diagnosis and patient stratification in clinical trials, and to serve as tools to identify and monitor the biochemical effect of the drug directly in patients. Biomarkers are also requested by regulatory authorities to serve as safety measurements. Molecular aberrations in the AD brain are reflected in the cerebrospinal fluid (CSF). Core CSF biomarkers include Abeta isoforms (Abeta40/Abeta42), soluble APP isoforms, Abeta oligomers and beta-site APP-cleaving enzyme 1 (BACE1). This article reviews recent research advances on core candidate CSF and plasma Abeta-related biomarkers, and gives a conceptual review on how to implement biomarkers in clinical trials in AD.
Language:
en
MeSH:
Alzheimer Disease; Amyloid beta-Protein; Biological Markers; Brain; Clinical Trials as Topic; Humans
ISSN:
1090-2430

Full metadata record

DC FieldValue Language
dc.contributor.authorHampel, Haralden
dc.contributor.authorShen, Yongen
dc.contributor.authorWalsh, Dominic Men
dc.contributor.authorAisen, Paulen
dc.contributor.authorShaw, Les Men
dc.contributor.authorZetterberg, Henriken
dc.contributor.authorTrojanowski, John Qen
dc.contributor.authorBlennow, Kajen
dc.date.accessioned2010-07-15T12:40:48Z-
dc.date.available2010-07-15T12:40:48Z-
dc.date.issued2010-06-
dc.identifier.citationBiological markers of amyloid beta-related mechanisms in Alzheimer's disease. 2010, 223 (2):334-46 Exp. Neurol.en
dc.identifier.issn1090-2430-
dc.identifier.pmid19815015-
dc.identifier.doi10.1016/j.expneurol.2009.09.024-
dc.identifier.urihttp://hdl.handle.net/10147/107733-
dc.description.abstractRecent research progress has given detailed knowledge on the molecular pathogenesis of Alzheimer's disease (AD), which has been translated into an intense, ongoing development of disease-modifying treatments. Most new drug candidates are targeted on inhibiting amyloid beta (Abeta) production and aggregation. In drug development, it is important to co-develop biomarkers for Abeta-related mechanisms to enable early diagnosis and patient stratification in clinical trials, and to serve as tools to identify and monitor the biochemical effect of the drug directly in patients. Biomarkers are also requested by regulatory authorities to serve as safety measurements. Molecular aberrations in the AD brain are reflected in the cerebrospinal fluid (CSF). Core CSF biomarkers include Abeta isoforms (Abeta40/Abeta42), soluble APP isoforms, Abeta oligomers and beta-site APP-cleaving enzyme 1 (BACE1). This article reviews recent research advances on core candidate CSF and plasma Abeta-related biomarkers, and gives a conceptual review on how to implement biomarkers in clinical trials in AD.-
dc.language.isoenen
dc.subject.meshAlzheimer Disease-
dc.subject.meshAmyloid beta-Protein-
dc.subject.meshBiological Markers-
dc.subject.meshBrain-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshHumans-
dc.titleBiological markers of amyloid beta-related mechanisms in Alzheimer's disease.en
dc.contributor.departmentDiscipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience (TCIN), Laboratory of Neuroimaging and Biomarker Research, Trinity College Dublin, Trinity Centre for Health Sciences, The Adelaide and Meath Hospital Incorporating The National Children's Hospital (AMiNCH), Dublin, Ireland; Department of Psychiatry, Alzheimer Memorial Center, Ludwig Maximilian University, Munich, Germany.en
dc.identifier.journalExperimental neurologyen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.